In hormone recep- tor-positive breast cancer, an ongoing trial is evaluating an antibody against IGF-1R with dasatinib and fulvestrant (NCT00903006).
It is known that IGF-1R is highly expressed and activated in hormone receptor-posi- tive tumors, no preclinical evidence supports this combi- nation.